The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 535-551

  Deng, Junli ^a   Wang, Li ^a   Chen, Hongmin ^a   Li, Lei ^a   Ma, Yiming ^a   Ni, Jie ^b,c   Li, Yong ^a,b,c  

^a ZHENGZHOU UNIVERSITY   (China)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Epithelial ovarian cancer; Metastasis; MUC1; Targeted cancer therapy; Tumour associated antigen

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APTAMER; BETA CATENIN; BIOLOGICAL MARKER; BISMUTH 213; CA 125 ANTIGEN; CANCER VACCINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; FLUOROURACIL; INTERCELLULAR ADHESION MOLECULE 1; IODINE 131; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595; MONOCLONAL ANTIBODY HMFG1; MUCIN 1; PLATINUM DERIVATIVE; PROTEIN P53; RADIOISOTOPE; RHENIUM 186; THERATOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN; YTTRIUM 90;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ASCITES; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIAGNOSTIC VALUE; DISEASE COURSE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG TARGETING; EARLY DIAGNOSIS; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HALF LIFE TIME; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; LOW DRUG DOSE; METASTASIS; MOLECULARLY TARGETED THERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN STRUCTURE; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR INVASION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; MUCIN-1; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84890310936     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9423-y     Document Type: Review

References (147)

1. Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. A Cancer Journal for Clinicians, 62, 10-29.
2. Bhoola, S., & Hoskins, W. J. (2006). Diagnosis and management of epithelial ovarian cancer. Obstetrics and Gynecology, 107, 1399-1410.
3. Yap, T. A., Carden, C. P., & Kaye, S. B. (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews. Cancer, 9, 167-181.
4. Harries, M., & Kaye, S. B. (2001). Recent advances in the treatment of epithelial ovarian cancer. Expert Opinions on Investigational Drugs, 10, 1715-1724.
5. Naora, H., & Montell, D. J. (2005). Ovarian cancer metastasis: integrating insights from disparate model organisms. Nature Reviews. Cancer, 5, 355-366.
6. Balkwill, F., Bast, R. C., Berek, J., Chenevix-Trench, G., Gore, M., Hamilton, T., et al. (2003). Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust. European Journal of Cancer, 39, 1818-1827.
7. Fleming, J. S., Beaugie, C. R., Haviv, I., Chenevix-Trench, G., & Tan, O. L. (2006). Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Molecular and Cellular Endocrinology, 247, 4-21.
8. Frederick, P. J., Straughn, J. M., Jr., Alvarez, R. D., & Buchsbaum, D. J. (2009). Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecological Oncology, 113, 384-390.
9. Taylor-Papadimitriou, J., Burchell, J., Miles, D. W., & Dalziel, M. (1999). MUC1 and cancer. Biochimica et Biophysica Acta, 1455, 301-313.
10. Gendler, S. J. (2001). MUC1, the renaissance molecule. Journal of Mammary Gland Biological Neoplasia, 6, 339-353.
11. Rahn, J. J., Dabbagh, L., Pasdar, M., & Hugh, J. C. (2001). The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer, 91, 1973-1982.
12. Li, Y., Cozzi, P. J., & Russell, P. J. (2010). Promising tumor-associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 30, 67-101.
13. Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., et al. (1993). Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. British Journal of Cancer, 68, 403-406.
14. Dong, Y., Walsh, M. D., Cummings, M. C., Wright, R. G., Khoo, S. K., Parsons, P. G., et al. (1997). Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. The Journal of Pathology, 183, 311-317.
15. Hu, X. F., Yang, E., Li, J., & Xing, P. X. (2006). MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Review of Anticancer Therapy, 6, 1261-1271.
16. Wang, L., Ma, J., Liu, F., Yu, Q., Chu, G., Perkins, A. C., et al. (2007). Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecological Oncology, 105, 695-702.
17. Van Elssen, C. H., Frings, P. W., Bot, F. J., Van de Vijver, K. K., Huls, M. B., Meek, B., et al. (2010). Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology, 57, 597-606.
18. Hollingsworth, M. A., & Swanson, B. J. (2004). Mucins in cancer: protection and control of the cell surface. Nature Reviews. Cancer, 4, 45-60.
19. Price, M. R., Hudecz, F., O'Sullivan, C., Baldwin, R. W., Edwards, P. M., & Tendler, S. J. (1990). Immunological and structural features of the protein core of human polymorphic epithelial mucin. Molecular Immunology, 27, 795-802.
20. Ligtenberg, M. J., Kruijshaar, L., Buijs, F., van Meijer, M., Litvinov, S. V., & Hilkens, J. (1992). Cell-associated episialin is a complex containing two proteins derived from a common precursor. The Journal of Biological Chemistry, 267, 6171-6177.
21. Gendler, S. J., Burchell, J. M., Duhig, T., Lamport, D., White, R., Parker, M., et al. (1987). Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proceedings of the National Academy of Sciences of the United States of America, 84, 6060-6064.
22. Gendler, S. J., Lancaster, C. A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., et al. (1990). Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. The Journal of Biological Chemistry, 265, 15286-15293.
23. Brockhausen, I., Yang, J. M., Burchell, J., Whitehouse, C., & Taylor-Papadimitriou, J. (1995). Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. European journal of biochemistry / FEBS, 233, 607-617.
24. Burchell, J., Poulsom, R., Hanby, A., Whitehouse, C., Cooper, L., Clausen, H., et al. (1999). An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology, 9, 1307-1311.
25. Gendler, S. J., Spicer, A. P., Lalani, E. N., Duhig, T., Peat, N., Burchell, J., et al. (1991). Structure and biology of a carcinoma-associated mucin, MUC1. The American Review of Respiratory Disease, 144, S42-47.
26. Hanisch, F. G., Stadie, T. R., Deutzmann, F., & Peter-Katalinic, J. (1996). MUC1 glycoforms in breast cancer - cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. European journal of biochemistry / FEBS, 236, 318-327.
27. Hanisch, F. G., & Muller, S. (2000). MUC1: the polymorphic appearance of a human mucin. Glycobiology, 10, 439-449.
28. Zrihan-Licht, S., Vos, H. L., Baruch, A., Elroy-Stein, O., Sagiv, D., Keydar, I., et al. (1994). Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. European journal of biochemistry / FEBS, 224, 787-795.
29. Smorodinsky, N., Weiss, M., Hartmann, M. L., Baruch, A., Harness, E., Yaakobovitz, M., et al. (1996). Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies. Biochemical and Biophysical Research Communications, 228, 115-121.
30. Oosterkamp, H. M., Scheiner, L., Stefanova, M. C., Lloyd, K. O., & Finstad, C. L. (1997). Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z). International journal of cancer. Journal international du cancer, 72, 87-94.
31. Baruch, A., Hartmann, M., Yoeli, M., Adereth, Y., Greenstein, S., Stadler, Y., et al. (1999). The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Research, 59, 1552-1561.
32. Baruch, A., Hartmann, M., Zrihan-Licht, S., Greenstein, S., Burstein, M., Keydar, I., et al. (1997). Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. International journal of cancer. Journal international du cancer, 71, 741-749.
33. Spicer, A. P., Duhig, T., Chilton, B. S., & Gendler, S. J. (1995). Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mammalian genome: official journal of the International Mammalian Genome Society, 6, 885-888.
34. Singh, P. K., & Hollingsworth, M. A. (2006). Cell surface-associated mucins in signal transduction. Trends in Cell Biology, 16, 467-476.
35. Hattrup, C. L., & Gendler, S. J. (2008). Structure and function of the cell surface (tethered) mucins. Annual Review of Physiology, 70, 431-457.
36. Kohlgraf, K. G., Gawron, A. J., Higashi, M., Meza, J. L., Burdick, M. D., Kitajima, S., et al. (2003). Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Research, 63, 5011-5020.
37. Mommers, E. C., Leonhart, A. M., von Mensdorff-Pouilly, S., Schol, D. J., Hilgers, J., Meijer, C. J., et al. (1999). Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. International journal of cancer. Journal international du cancer, 84, 466-469.
38. Gaemers, I. C., Vos, H. L., Volders, H. H., van der Valk, S. W., & Hilkens, J. (2001). A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. The Journal of Biological Chemistry, 276, 6191-6199.
39. Wesseling, J., van der Valk, S. W., Vos, H. L., Sonnenberg, A., & Hilkens, J. (1995). Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. The Journal of Cell Biology, 129, 255-265.
40. Feng, H., Ghazizadeh, M., Konishi, H., & Araki, T. (2002). Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Japanese Journal of Clinical Oncology, 32, 525-529.
41. McDermott, K. M., Crocker, P. R., Harris, A., Burdick, M. D., Hinoda, Y., Hayashi, T., et al. (2001). Overexpression of MUC1 reconfigures the binding properties of tumor cells. International journal of cancer. Journal international du cancer, 94, 783-791.
42. Zhang, K., Baeckstrom, D., Brevinge, H., & Hansson, G. C. (1996). Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. Journal of Cell Biochemistry, 60, 538-549.
43. Brinkman-Van der Linden, E. C., & Varki, A. (2000). New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. The Journal of Biological Chemistry, 275, 8625-8632.
44. Budiu, R.A., Elishaev, E., Brozick, J., Lee, M., Edwards, R.P., Kalinski, P., et al. (2012). Immunobiology of human mucin 1 in a preclinical ovarian tumor model. Oncogene. doi: 10.1038/onc.2012.397.
45. Karsten, U., von Mensdorff-Pouilly, S., & Goletz, S. (2005). What makes MUC1 a tumor antigen? Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 26, 217-220.
46. van de Wiel-van Kemenade, E., Ligtenberg, M. J., de Boer, A. J., Buijs, F., Vos, H. L., Melief, C. J., et al. (1993). Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. Journal of Immunology, 151, 767-776.
47. Hughes, O. D., Bishop, M. C., Perkins, A. C., Wastie, M. L., Denton, G., Price, M. R., et al. (2000). Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 18, 363-370.
48. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 10, 942-949.
49. Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 18538-18543.
50. Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., et al. (2007). Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Research, 67, 8900-8905.
51. Ren, J., Agata, N., Chen, D., Li, Y., Yu, W. H., Huang, L., et al. (2004). Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell, 5, 163-175.
52. Wei, X., Xu, H., & Kufe, D. (2005). Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell, 7, 167-178.
53. Yin, L., Huang, L., & Kufe, D. (2004). MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. The Journal of Biological Chemistry, 279, 45721-45727.
54. Kalra, A. V., & Campbell, R. B. (2007). Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. British Journal of Cancer, 97, 910-918.
55. Kalra, A. V., & Campbell, R. B. (2009). Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. European Journal of Cancer, 45, 164-173.
56. Hait, W. N., Jin, S., & Yang, J. M. (2006). A matter of life or death (or both): understanding autophagy in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 12, 1961-1965.
57. Peracchio, C., Alabiso, O., Valente, G., & Isidoro, C. (2012). Involvement of autophagy in ovarian cancer: a working hypothesis. Journal of Ovarian Research, 5, 22.
58. Amaravadi, R. K. (2008). Autophagy-induced tumor dormancy in ovarian cancer. Journal of Clinical Investigation, 118, 3837-3840.
59. Yin, L., Kharbanda, S., & Kufe, D. (2009). MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. International Journal of Oncology, 34, 1691-1699.
60. Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews. Cancer, 9, 265-273.
61. Vergara, D., Merlot, B., Lucot, J. P., Collinet, P., Vinatier, D., Fournier, I., et al. (2010). Epithelial-mesenchymal transition in ovarian cancer. Cancer Letters, 291, 59-66.
62. Roy, L. D., Sahraei, M., Subramani, D. B., Besmer, D., Nath, S., Tinder, T. L., et al. (2011). MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene, 30, 1449-1459.
63. Rajabi, H., Ahmad, R., Jin, C., Joshi, M. D., Guha, M., Alam, M., et al. (2012). MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate, 72, 1659-1668.
64. Ahmed, N., Abubaker, K., Findlay, J., & Quinn, M. (2010). Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Current Cancer Drug Targets, 10, 268-278.
65. Davidson, B., Trope, C. G., & Reich, R. (2012). Epithelial- mesenchymal transition in ovarian carcinoma. Front Oncology, 2, 33.
66. Carraway, K. L., 3rd, Funes, M., Workman, H. C., & Sweeney, C. (2007). Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Current Topics in Developmental Biology, 78, 1-22.
67. Yamamoto, M., Bharti, A., Li, Y., & Kufe, D. (1997). Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. The Journal of Biological Chemistry, 272, 12492-12494.
68. Schroeder, J. A., Adriance, M. C., Thompson, M. C., Camenisch, T. D., & Gendler, S. J. (2003). MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene, 22, 1324-1332.
69. Li, Y., Kuwahara, H., Ren, J., Wen, G., & Kufe, D. (2001). The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. The Journal of Biological Chemistry, 276, 6061-6064.
70. Li, Y., Ren, J., Yu, W., Li, Q., Kuwahara, H., Yin, L., et al. (2001). The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. The Journal of Biological Chemistry, 276, 35239-35242.
71. Li, Y., & Kufe, D. (2001). The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochemical and Biophysical Research Communications, 281, 440-443.
72. Ren, J., Li, Y., & Kufe, D. (2002). Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. The Journal of Biological Chemistry, 277, 17616-17622.
73. Schroeder, J. A., Thompson, M. C., Gardner, M. M., & Gendler, S. J. (2001). Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. The Journal of Biological Chemistry, 276, 13057-13064.
74. Li, Y., Yu, W. H., Ren, J., Chen, W., Huang, L., Kharbanda, S., et al. (2003). Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Molecular Cancer Research, 1, 765-775.
75. Pochampalli, M. R., el Bejjani, R. M., & Schroeder, J. A. (2007). MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene, 26, 1693-1701.
76. Roepstorff, K., Grovdal, L., Grandal, M., Lerdrup, M., & van Deurs, B. (2008). Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochemistry and Cell Biology, 129, 563-578.
77. Hattrup, C. L., & Gendler, S. J. (2006). MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Research, 8, R37.
78. Pochampalli, M. R., Bitler, B. G., & Schroeder, J. A. (2007). Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Research, 67, 6591-6598.
79. Bitler, B. G., Goverdhan, A., & Schroeder, J. A. (2010). MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. Journal of Cell Science, 123, 1716-1723.
80. Bienz, M. (2005). beta-Catenin: a pivot between cell adhesion and Wnt signalling. Current Biology, 15, R64-67.
81. Moon, R. T., Kohn, A. D., De Ferrari, G. V., & Kaykas, A. (2004). WNT and beta-catenin signalling: diseases and therapies. Nature Reviews Genetics, 5, 691-701.
82. Hulsken, J., Behrens, J., & Birchmeier, W. (1994). Tumor-suppressor gene products in cell contacts: the cadherin-APC-armadillo connection. Current Opinion in Cell Biology, 6, 711-716.
83. Wen, Y., Caffrey, T. C., Wheelock, M. J., Johnson, K. R., & Hollingsworth, M. A. (2003). Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. The Journal of Biological Chemistry, 278, 38029-38039.
84. Huang, L., Chen, D., Liu, D., Yin, L., Kharbanda, S., & Kufe, D. (2005). MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Research, 65, 10413-10422.
85. Li, Y., Liu, D., Chen, D., Kharbanda, S., & Kufe, D. (2003). Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene, 22, 6107-6110.
86. Li, Y., Bharti, A., Chen, D., Gong, J., & Kufe, D. (1998). Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Molecular and Cellular Biology, 18, 7216-7224.
87. Havrilesky, L. J., Whitehead, C. M., Rubatt, J. M., Cheek, R. L., Groelke, J., He, Q., et al. (2008). Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology, 110, 374-382.
88. Rein, B. J., Gupta, S., Dada, R., Safi, J., Michener, C., & Agarwal, A. (2011). Potential markers for detection and monitoring of ovarian cancer. Journal of Oncology, 2011, 475983.
89. Moore, L. E., Pfeiffer, R. M., Zhang, Z., Lu, K. H., Fung, E. T., & Bast, R. C., Jr. (2012). Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer, 118, 91-100.
90. Cannistra, S. A. (2004). Cancer of the ovary. The New England Journal of Medicine, 351, 2519-2529.
91. Fisken, J., Leonard, R. C., Badley, A., Jonrup, I., Aspinall, L., Sturgeon, C., et al. (1991). Serological monitoring of epithelial ovarian cancer. Disease Markers, 9, 175-190.
92. Vuento, M. H., Stenman, U. H., Pirhonen, J. P., Makinen, J. I., Laippala, P. J., & Salmi, T. A. (1997). Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecological Oncology, 64, 141-146.
93. Moore, R. G., & Maclaughlan, S. (2010). Current clinical use of biomarkers for epithelial ovarian cancer. Current Opinion in Oncology, 22, 492-497.
94. Fritz-Rdzanek, A., Grzybowski, W., Beta, J., Durczynski, A., & Jakimiuk, A. (2012). HE4 protein and SMRP: potential novel biomarkers in ovarian cancer detection. Oncology Letters, 4, 385-389.
95. Baldus, S. E., Engelmann, K., & Hanisch, F. G. (2004). MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Critical Reviews in Clinical Laboratory Sciences, 41, 189-231.
96. Sekine, H., Hayes, D. F., Ohno, T., Keefe, K. A., Schaetzl, E., Bast, R. C., et al. (1985). Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 3, 1355-1363.
97. Bast, R. C., Jr., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981). Reactivity of a monoclonal antibody with human ovarian carcinoma. Journal of Clinical Investigation, 68, 1331-1337.
98. Fisken, J., Roulston, J. E., Sturgeon, C., Badley, R. A., Jonrup, I., Aspinall, L., et al. (1993). The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125. British Journal of Cancer, 67, 1065-1070.
99. Richards, E. R., Devine, P. L., Quin, R. J., Fontenot, J. D., Ward, B. G., & McGuckin, M. A. (1998). Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer immunology, immunotherapy: CII, 46, 245-252.
100. Wandall, H. H., Blixt, O., Tarp, M. A., Pedersen, J. W., Bennett, E. P., Mandel, U., et al. (2010). Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Research, 70, 1306-1313.
101. Budiu, R. A., Mantia-Smaldone, G., Elishaev, E., Chu, T., Thaller, J., McCabe, K., et al. (2011). Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer immunology, immunotherapy: CII, 60, 975-984.
102. Danielczyk, A., Stahn, R., Faulstich, D., Loffler, A., Marten, A., Karsten, U., et al. (2006). PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer immunology, immunotherapy: CII, 55, 1337-1347.
103. Karsten, U., Diotel, C., Klich, G., Paulsen, H., Goletz, S., Muller, S., et al. (1998). Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Research, 58, 2541-2549.
104. Jeschke, U., Wiest, I., Schumacher, A. L., Kupka, M., Rack, B., Stahn, R., et al. (2012). Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab. Anticancer Research, 32, 2185-2189.
105. Croghan, G. A., Wingate, M. B., Gamarra, M., Johnson, E., Chu, T. M., Allen, H., et al. (1984). Reactivity of monoclonal antibody F36/22 with human ovarian adenocarcinomas. Cancer Research, 44, 1954-1962.
106. Friedman, E. L., Hayes, D. F., & Kufe, D. W. (1986). Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Research, 46, 5189-5194.
107. Ward, B. G., Lowe, D. G., & Shepherd, J. H. (1987). Patterns of expression of a tumor associated antigen, defined by the monoclonal antibody HMFG2, in human epithelial ovarian carcinoma. Comparison with expression of the HMFG1, AUA1 and F36/22 antigens. Cancer, 60, 787-793.
108. Ichige, K., Perey, L., Vogel, C. A., Buchegger, F., & Kufe, D. (1995). Expression of the DF3-P epitope in human ovarian carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research, 1, 565-571.
109. Drapkin, R., Crum, C. P., & Hecht, J. L. (2004). Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Human Pathology, 35, 1014-1021.
110. Lau, S. K., Weiss, L. M., & Chu, P. G. (2004). Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. American Journal of Clinical Pathology, 122, 61-69.
111. Tornos, C., Soslow, R., Chen, S., Akram, M., Hummer, A. J., Abu-Rustum, N., et al. (2005). Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. The American Journal of Surgical Pathology, 29, 1482-1489.
112. Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., et al. (2004). Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical cancer research: an official journal of the American Association for Cancer Research, 10, 3291-3300.
113. Rosen, D. G., Wang, L., Atkinson, J. N., Yu, Y., Lu, K. H., Diamandis, E. P., et al. (2005). Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecological Oncology, 99, 267-277.
114. Takano, M., Fujii, K., Kita, T., Kikuchi, Y., & Uchida, K. (2004). Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncology Reports, 12, 1177-1182.
115. Tamada, Y., Takeuchi, H., Suzuki, N., Susumu, N., Aoki, D., & Irimura, T. (2007). Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Science, 98, 1586-1591.
116. Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., et al. (2009). The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical cancer research: an official journal of the American Association for Cancer Research, 15, 5323-5337.
117. Mabuchi, S., & Kimura, T. (2010). Treatment of ovarian cancer by monoclonal antibodies. Discovery Medicine, 9, 197-203.
118. Mabuchi, S., Morishige, K., & Kimura, T. (2010). Use of monoclonal antibodies in the treatment of ovarian cancer. Current Opinion in Obstetrics and Gynecology, 22, 3-8.
119. Perkins, A. C., Symonds, I. M., Pimm, M. V., Price, M. R., Wastie, M. L., & Symonds, E. M. (1993). Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nuclear Medicine Communications, 14, 578-586.
120. Song, Y. J., Qu, C. F., Rizvi, S. M., Li, Y., Robertson, G., Raja, C., et al. (2006). Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Letters, 234, 176-183.
121. Song, E. Y., Qu, C. F., Rizvi, S. M., Raja, C., Beretov, J., Morgenstern, A., et al. (2008). Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biology & Therapy, 7, 76-80.
122. Wang, L., Chen, H., Liu, F., Madigan, M. C., Power, C. A., Hao, J., et al. (2011). Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Letters, 300, 122-133.
123. Wang, L., Chen, H., Pourgholami, M. H., Beretov, J., Hao, J., Chao, H., et al. (2011). Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One, 6, e24405.
124. Nicholson, S., Bomphray, C. C., Thomas, H., McIndoe, A., Barton, D., Gore, M., et al. (2004). A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer immunology, immunotherapy: CII, 53, 809-816.
125. Epenetos, A. A., Britton, K. E., Mather, S., Shepherd, J., Granowska, M., Taylor-Papadimitriou, J., et al. (1982). Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet, 2, 999-1005.
126. Janssen, M. L., Pels, W., Massuger, L. F., Oyen, W. J., Boonstra, H., Corstens, F. H., et al. (2003). Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. International Journal of Gynecological Cancer, 13, 607-613.
127. Stewart, J. S., Hird, V., Snook, D., Dhokia, B., Sivolapenko, G., Hooker, G., et al. (1990). Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 8, 1941-1950.
128. Epenetos, A. A., Hird, V., Lambert, H., Mason, P., & Coulter, C. (2000). Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. International Journal of Gynecological Cancer, 10, 44-46.
129. Verheijen, R. H., Massuger, L. F., Benigno, B. B., Epenetos, A. A., Lopes, A., Soper, J. T., et al. (2006). Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 24, 571-578.
130. Oei, A. L., Verheijen, R. H., Seiden, M. V., Benigno, B. B., Lopes, A.,
131. Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., & Brugger, W. (2000). Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 96, 3102-3108.
132. Holmberg, L. A., Oparin, D. V., Gooley, T., & Sandmaier, B. M. (2003). The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clinical Breast Cancer, 3(Suppl 4), S144-151.
133. Vlad, A. M., Kettel, J. C., Alajez, N. M., Carlos, C. A., & Finn, O. J. (2004). MUC1 immunobiology: from discovery to clinical applications. Advances in Immunology, 82, 249-293.
134. Sabbatini, P. J., Ragupathi, G., Hood, C., Aghajanian, C. A., Juretzka, M., Iasonos, A., et al. (2007). Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research, 13, 4170-4177.
135. Oei, A. L., Sweep, F. C., Thomas, C. M., Boerman, O. C., & Massuger, L. F. (2008). The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). International Journal of Oncology, 32, 1145-1157.
136. Raina, D., Ahmad, R., Joshi, M. D., Yin, L., Wu, Z., Kawano, T., et al. (2009). Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Research, 69, 5133-5141.
137. Bitler, B. G., Menzl, I., Huerta, C. L., Sands, B., Knowlton, W., Chang, A., et al. (2009). Intracellular MUC1 peptides inhibit cancer progression. Clinical cancer research: an official journal of the American Association for Cancer Research, 15, 100-109.
138. Osborne, S. E., Matsumura, I., & Ellington, A. D. (1997). Aptamers as therapeutic and diagnostic reagents: problems and prospects. Current Opinion in Chemical Biology, 1, 5-9.
139. Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T. N., Lavan, D. A., & Langer, R. (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Research, 64, 7668-7672.
140. Huang, Y. F., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., et al. (2009). Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochemistry, 10, 862-868.
141. Ferreira, C. S., Matthews, C. S., & Missailidis, S. (2006). DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 27, 289-301.
142. Ferreira, C. S., Cheung, M. C., Missailidis, S., Bisland, S., & Gariepy, J. (2009). Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Research, 37, 866-876.
143. Savla, R., Taratula, O., Garbuzenko, O., & Minko, T. (2011). Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. Journal of controlled release: official journal of the Controlled Release Society, 153, 16-22.
144. Hu, Y., Duan, J., Zhan, Q., Wang, F., Lu, X., & Yang, X. D. (2012). Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One, 7, e31970.
145. Liu, N., Zhou, C., Zhao, J., & Chen, Y. (2012). Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Investigation, 30, 577-582.
146. Zhao, Q., Guo, X., Nash, G. B., Stone, P. C., Hilkens, J., Rhodes, J. M., et al. (2009). Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Research, 69, 6799-6806.
147. Zhao, Q., Barclay, M., Hilkens, J., Guo, X., Barrow, H., Rhodes, J. M., et al. (2010). Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Molecular Cancer, 9, 154.